Description of neurotoxicity in a series of patients treated with CAR T-cell therapy
Catherine Belin,Perrine Devic,Xavier Ayrignac,Amélie Dos Santos,Adrien Paix,Lila Sirven-Villaros,Claire Simard,Sylvain Lamure,Thomas Gastinne,Renata Ursu,Colette Berger,Laura Platon,Benoît Tessoulin,Elie Azoulay,Florent Wallet,Catherine Thieblemont,Emmanuel Bachy,Guillaume Cartron,David A. Laplaud,Antoine F. Carpentier
DOI: https://doi.org/10.1038/s41598-020-76055-9
IF: 4.6
2020-11-04
Scientific Reports
Abstract:Abstract Chimeric antigen receptor-modified T (CAR T) cell therapy is a highly promising treatment for haematological malignancies but is frequently associated with cytokine release syndrome and neurotoxicity. Between July 2018 and July 2019, all patients treated with CD19-targeted CAR T-cell therapy for relapsing lymphoma were followed-up longitudinally to describe neurological symptoms and their evolution over time. Four different French centres participated and 84 patients (median age 59 years, 31% females) were included. Neurotoxicity, defined as the presence of at least one neurological symptom appearing after treatment infusion, was reported in 43% of the patients. The median time to onset was 7 days after infusion with a median duration of 6 days. More than half of the patients (64%) had grade 1–2 severity and 34% had grade 3–4. CRS was observed in 80% of all patients. The most frequent neurological symptoms were cognitive signs, being severe in 36%, and were equally distributed between language disorders and cognitive disorders without language impairment. Non-pyramidal motor disorders, severe in 11%, were reported in 42% of the patients. Elevation of C-reactive protein (CRP) within 4 days after treatment was significantly correlated with the occurrence of grade 3–4 neurotoxicity. Although sometimes severe, neurotoxicity was almost always reversible. The efficacy of steroids and antiepileptic drugs remains unproven in the management of neurotoxicity. Neurotoxicity associated with CAR T-cell therapies occurs in more than 40% of patients. The clinical pattern is heterogeneous but cognitive disorders (not limited to language disorders) and, to a minor degree, non-pyramidal motor disorders, appeared as a signature of severe neurotoxicity.
multidisciplinary sciences